Research & Development

CURRENT PROJECTS

R&D programs sponsored by national and international programs:

MULTIPLEXED PANELS IN OTHER LIQUIDS

Generation of new multiplex assays with prognostic, diagnostic & predictive value on biological fluids other than blood, in patients with solid tumours.

DIPCAN

To develop an algorithm based on artificial intelligence methods to guide physicians on the decision-making process in the clinical setting.

Inmuno & Tumor Micro-environment

Development of a platform for both better patient stratification & clinical validation efficiency of immuno oncology drugs.

MULTIPLEXED PANELS IN OTHER LIQUIDS

Generation of new multiplex assays with prognostic, diagnostic & predictive value on biological fluids other than blood, in patients with solid tumours.

DIPCAN

To develop an algorithm based on artificial intelligence methods to guide physicians on the decision-making process in the clinical setting.

R&D programs sponsored by:

EARLY DETECTION

Development of a liquid biopsy assay for the early detection of lung cancer.

NEUROENDOCRINE

Molecular classification neuroendocrine tumors of the lung.

EARLY DETECTION

Development of a liquid biopsy assay for the early detection of lung cancer.

TP53

Testing new therapeutic strategies for P53-mutated NSCLC patients.

NEUROENDOCRINE

Molecular classification neuroendocrine tumors of the lung.

Last PROJECTS

Sponsored by national and international programs:

ELBA: European Liquid Biopsies Academy

To move the promising technology of liquid biopsies out of its infancy and bring it to the clinic with a further focus on Non-Small Cell Lung Cancer (NSCLC) early diagnosis. Liquid biopsies offer a minimally invasive, safe, and sensitive alternative or complementary approach for tissue biopsies.

multiplexed
panels IN BLOOD

Development of multiplexed panes for diagnostics in liquid biopsy and expansion of the single mutation test for the monitorization of not microcytic lung cancer.

PREBIOM

Development of a platform for both better patient stratification & clinical validation efficiency of immuno oncology drugs.

DELTAMET

Design and validation of a new diagnostics assay for the stratification of lung cancer patients presenting resistance to EGFR therapy.

PATHFLOW

Artificial intelligence (AI)-based digital tools for workflow improvement in pathological image.